Lv1
30 积分 2025-04-09 加入
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims
3个月前
已完结
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
4个月前
已完结
Risk of ocular adverse events with aromatase inhibitors
5个月前
已完结
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
10个月前
已完结
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
1年前
已完结
皖公网安备34019202002308
